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A B S T R A C T
Background: The Singapore GSDCS score was developed to enable clinicians predict the risk of nosocomial
multidrug-resistant Gram-negative bacilli (RGNB) infection in critically ill patients. We aimed to validate
this score in a UK setting.
Method: A retrospective case–control study was conducted including patients who stayed for more than
24 h in intensive care units (ICUs) across two tertiary National Health Service hospitals in London, UK
(April 2011–April 2016). Cases with RGNB and controls with sensitive Gram-negative bacilli (SGNB)
infection were identified.
Results: The derived GSDCS score was calculated from when there was a step change in antimicrobial
therapy in response to clinical suspicion of infection as follows: prior Gram-negative organism, Surgery,
Dialysis with end-stage renal disease, prior Carbapenem use and intensive care Stay of more than 5 days.
A total of 110 patients with RGNB infection (cases) were matched 1:1 to 110 geotemporally chosen
patients with SGNB infection (controls). The discriminatory ability of the prediction tool by receiver
operating characteristic curve analysis in our validation cohort was 0.75 (95% confidence interval 0.65–
0.81), which is comparable with the area under the curve of the derivation cohort (0.77). The GSDCS score
differentiated between low- (0–1.3), medium- (1.4–2.3) and high-risk (2.4–4.3) patients for RGNB
infection (P < 0.001) in a UK setting.
Conclusion: A simple bedside clinical prediction tool may be used to identify and differentiate patients at
low, medium and high risk of RGNB infection prior to initiation of prompt empirical antimicrobial
therapy in the intensive care setting.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Antimicrobial resistance (AMR) poses a profound global threat
to economic security, human and animal health [1]. Rates of* Corresponding author at: Antimicrobial Pharmacodynamics and Therapeutics,
Department of Molecular and Clinical Pharmacology, University of Liverpool,
Liverpool L69 3GE, UK.
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higher in the intensive care unit (ICU) setting, leading to broader
empirical antimicrobial therapy [2]. The World Health Organisa-
tion (WHO) highlighted multidrug-resistant (MDR) Gram-negative
bacilli as ‘Priority 1 Pathogens’ and recommended innovative tools
be developed to support clinical decision-making around the
appropriate use of antimicrobial drugs [3]. Clinical prediction tools
are used widely in the ICU to stratify patient risk for a variety of
conditions [4,5] and may prove valuable to promptly assess the risk
of MDR infection [6,7] prior to much anticipated rapid diagnosticy for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-
 tool to determine the risk of nosocomial multidrug-resistant Gram-
trol study, J Global Antimicrob Resist (2020), https://doi.org/10.1016/
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ment of the risk of infection being caused by multidrug-resistant
Gram-negative bacilli (RGNB) was developed and validated in
Singapore [6]. We aimed to validate this score in a UK setting.
2. Method
The cohort of patients were from a 5-year retrospective study
in ICUs across two large National Health Service tertiary referral
teaching hospitals in London, UK, serving a population of almost 2
million. The ICUs at both Hospital A and B admit a heterogeneous
cohort of patients with medical and surgical problems with an
RGNB prevalence of 0.03%. All patients are screened on admission
and weekly to assess carriage of methicillin-resistant Staphylo-
coccus aureus (MRSA) and carbapenemase-producing Enterobac-
teriaceae (CPE), as per local policy with strict infection control
policies being in place. All consecutive patients aged over 21 years
admitted to the ICU in Hospital A or B, and who stayed for more
than 24 h, from 5 April 2011 to 6 April 2016 were included. Those
with GNB within 24 h prior to ICU admission and subsequent to
ICU discharge were excluded. Microbiology data representing
colonisation (rectal screening for CPE, those with no symptoms/
signs of infection) were excluded. The four Gram-negative
organisms mentioned in the original score were included for this
study (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeru-
ginosa and Acinetobacter baumannii) [6]. RGNB was defined as
acquired non-susceptibility to at least one drug in three or more
antibiotic categories [8]. The three classes of antibiotics were
cephalosporins (ceftazidime), fluoroquinolones (ciprofloxacin)
and aminoglycosides (gentamicin). Sensitive Gram-negative bacilli
(SGNB) were defined as the organisms that did not meet the
criteria for RGNB.
Medical records were reviewed to identify those with RGNB for
whom antimicrobial treatment had been initiated/changed based
on clinical suspicion of infection within 24 h of the culture being
taken (cases). A distinct group of patients with isolated SGNB
(controls) from clinical specimens were identified geotemporallyTable 1
Patient, infection characteristics and risk factors.
Variable SGNB (n




Median BMI (range) 24.5 (16.
Type of admission, n (%) 
Planned 16 (14.8)
Unplanned 92 (85.2
Site of infection 
Blood (including intravascular catheter-related) 11 (10) 
Pneumonia 72 (65.5
Urine 11 (10) 
Complicated skin and soft tissue (including surgical site) 3 (2.7) 
Others (including intra-abdominal) 13 (11.8)
Causative organism, n (%) 
Acinetobacter baumannii 1 (0.9) 
Escherichia coli 38 (34.6
Klebsiella pneumoniae 31 (28.2
Pseudomonas aeruginosa 40 (36.3
Risk factors and GSDCS score categories
Presence of any GNB within 6 months, n (%) 24 (21.8)
Surgery in this admission before RGNB, n (%) 57 (51.8)
Dialysis with end-stage renal disease, n (%) 3 (2.7) 
Carbapenems within 6 months, n (%) 29 (26.4
Stay in ICU > 5 days, n (%) 53 (48.2
BMI, body mass index; ICU, intensive care unit; RGNB, resistant Gram-negative bacilli;
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collection for the risk score and were matched 1:1 with the cases.
Data were collected from electronic medical records (Acubase1),
hospital pharmacy inpatient medication records and the
Sunquest1 laboratory information management system by inves-
tigators blinded to the results of the other components of the score
and corroborated through detailed case note analysis. The risk
score was calculated from the date of the step change in
antimicrobial therapy, which preceded final culture and sensitivity
results.
2.1. Statistical analysis
Baseline variables were represented as means/medians for
continuous variables and proportions for categorical variables. Chi
square (χ2)/Fisher's exact tests were used to compare proportions,
and Student t-tests/Wilcoxon rank-sum tests were used for
continuous variables as appropriate. We calculated the GSDCS
risk score based on the regression coefficients described by
Vasudevan et al. [6]. One point was allocated for the presence of
prior GNB in a clinical sample or prior administration of
carbapenems within 6 months, with 0.6 points if the patient
had undergone surgery before isolation of GNB, 0.7 points for prior
dialysis with end-stage renal disease and 2 points for a stay of more
than 5 days in the ICU prior to isolation of GNB. Points were
summated to calculate the final score for each patient, and 1 point
was subtracted for patients who had been admitted to the ICU for
more than 5 days prior to isolation of GNB and with prior exposure
to a carbapenem. The discriminatory ability was then assessed by a
receiver operating characteristic (ROC) curve analysis and by
measuring the area under the curve (AUC). The sensitivity,
specificity and the likelihood ratios were then calculated for the
different risk categories. Analyses were conducted using STATA
14.2 (STATA Corp, College Station, TX, USA). There is no widely
acceptable approach to estimate sample size required for risk score
validation studies, although limited evidence suggests a minimum
of 100 events (RGNB) and 100 nonevents (SGNB) [9]. = 110) (controls) RGNB (n = 110) (cases) P-value
–85) 65 (24–86) 0.49
) 41 (37.3)
) 69 (62.7) 0.78















 34 (30.9) 0.13
 92 (83.6) <0.001
14 (12.7) 0.005
) 76 (69.1) <0.001
) 84 (76.4) <0.001
 SGNB, sensitive Gram-negative bacilli.
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A total of 4249 adult patients were admitted for more than 24 h
to the ICUs of Hospital A and B during the study period. Medical
records were reviewed for those with a positive RGNB culture that
met inclusion criteria (n = 133), and 110 of them had antimicrobial
treatment initiated/changed due to clinical suspicion of infection
within 24 h of the RGNB culture being taken (cases). Medical
records were reviewed for patients that met inclusion criteria with
a positive culture yielding SGNB (n = 198). A total of 110 patients
with RGNB infection (cases) were geotemporally matched 1:1 to
110 patients with SGNB infection (controls).
The characteristics of patients with RGNB and SGNB included in
this validation study are presented in Table 1. RGNB infections were
most frequently pneumonia (58.1%), followed by complicated skin
and soft tissue infections (16.4%) and urinary tract infections
(12.7%). SGNB infections were more frequently pneumonia (65.5%),
followed by intra-abdominal infections (11.8%), blood (10%) and
urinary tract infections (10%). Both groups had comparably low
incidence of bacteraemia, and infections related to intravascularFig. 1. Performance of GSDCS score for predicting RG
Please cite this article in press as: S.E. Boyd, et al., Validating a prediction
negative bacilli infection in critically ill patients: A retrospective case–con
j.jgar.2020.07.010catheters (RGNB: 1, SGNB: 2). These were classified as blood for the
final analyses.
By ROC curve analysis, the AUC for the GSDCS score was found
to be 0.75 [95% confidence interval (CI) 0.65–0.81] (Fig. 1), when
applied to predict RGNB infection in this cohort of ICU patients.
The proportion of RGNB patients in different GSDCS risk
categories is shown in Fig. 2. The score reliably differentiated
between patients at low, medium and high risk.
4. Discussion
The discriminatory ability (AUC) of the GSDCS score in our
cohort was 0.75, which is comparable with the AUC from the
cohort in the original risk score study (0.77). The GSCDS score,
which was developed in Singapore, performed well for identifying
risk of nosocomial infection caused by RGNB in our critically ill
population in London. The score reliably differentiated between
patients at low, medium and high risk. Furthermore, baseline
characteristics and causative organisms among patients in each
group were comparable.NB infection in ICU patients aged over 21 years.
 tool to determine the risk of nosocomial multidrug-resistant Gram-
trol study, J Global Antimicrob Resist (2020), https://doi.org/10.1016/
Fig. 2. Prevalence in different risk categories based on the GSDCS score.
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scoring systems for RGNB infection among critically ill patients
has been developed for patients with blood stream infections
[7], those on ventilator [10] and those with healthcare-
associated pneumonia [11]. However, the applicability of these
tools to other anatomical sites of nosocomial RGNB infections,
within the ICU setting, remains restricted. The original
derivation and validation of the GSDCS score included a variety
of infections caused by four of the most common nosocomial
Gram-negative organisms. A key advantage of this validation
was inclusion of patients with different sites of infection which
maintained predictive ability of the score to differentiate risk.
The clinical utility is clear, as the site of infection may not be
apparent when empirical prescribing decisions need to be
made. Choosing appropriate empirical treatment will help
improve outcomes in critically ill patients and help reduce any
collateral damage related to ineffective therapy or antimicro-
bial drug resistance.
Previous studies designed to identify risk factors for RGNB
infection in ICU have been limited by their specificity to specific
patient populations or a single species of bacteria [12–16]. In
these studies, disparities exist between definitions for MDR
Gram-negative organisms, making comparisons between differ-
ent predictive scores difficult. We adopted the international
expert standard definition for acquired non-susceptibility to
define MDR Gram-negative organisms [8], allowing for reliable
comparison to the original study [6] in addition to setting a
widely accepted standard for future risk scores. Earlier stratifica-
tion of patients based on risk of RGNB can provide clinicians
additional information to help inform appropriate empirical
prescribing decisions. The date that the risk score was calculated
preceded the final culture and sensitivity results. This is
important as it reflects the predictive value and clinical utility
for identifying patients who may benefit from broader-spectrum
antimicrobial therapy before final culture and sensitivity results
are confirmed, which can take up to 48 h from when the
laboratory receives the culture.Please cite this article in press as: S.E. Boyd, et al., Validating a prediction
negative bacilli infection in critically ill patients: A retrospective case–con
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Data on illness severity scores, including APACHE and SOFA,
were not included in this validation study as they do not reliably
predict risk of infection caused by MDR bacteria in critically ill
patients [17]. The original score and our validation excluded
patients aged less than 21 years and hence requires further
validation in younger adults and in paediatric populations, for
whom different risk factors may exist. Notably, the GSDCS risk
score is only validated for the four GNBs and should be used with
caution in settings where the prevalence of resistance from
another GNB is of concern. The score should not be used during
outbreaks, as it has not been validated for this application.
Variation in patient population may have implications on the
predictive value of the score.
The limitations associated with this being a retrospective study
should be considered. An observational validation study found
limited applicability of the American Thoracic Society (ATS)/
Infectious Diseases Society of America (ISDA) score when it was
applied prospectively to predict MDR bacterial infection or
colonisation in patients on admission to the ICU [18], and hence
de-escalation of broad-spectrum agents remains a challenge in
critical care settings [19]. The ATS/IDSA score did not differentiate
between MDR infection and colonisation, whereas the GSDCS score
is validated only in patients suspected of having an infection. This
study included SGNB as control patients compared to the controls
being with no infection in the study conducted by Vasudevan et al.
However, we found that this tool effectively predicted patients
with RGNB infection when compared with SGNB. The patients
were classified into the distinct risk categories based on the cut-off
presented in the original tool, and the prevalence in each setting
needs to be considered when considering predictive values.
6. Conclusions
The GSDCS scoring system is a promising and effective tool for
predicting risk of RGNB infection in ICU patients and may be tool to determine the risk of nosocomial multidrug-resistant Gram-
trol study, J Global Antimicrob Resist (2020), https://doi.org/10.1016/
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machine-learning capabilities, allowing for refinement of predic-
tive ability over time [20]. Targeting broad-spectrum antimicrobial
therapy for patients at highest risk would spare others from
‘collateral damage’. To our knowledge, this is the only externally
validated scoring system to predict risk of infection caused by
RGNB across a range of infection sites in a mixed population of
critically ill patients.
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